Related to ImmunoCellular Therapeutics Taps UPenn to Progress Mid-Stage Glioblastoma Candidate

• Scripps and UPenn Researchers Awarded $8M to Develop Drugs for Tobacco Addiction
  
• Scientists Discover Potential New Gene Target Against Brain Tumor Stem Cells
  
• Inovio Expects to Net $23M from Direct Registered Offering to Single Investor
  
• Soligenix Nabs Exclusive License to Vaccine Thermostabilization Technology
  
• To-BBB Scores €4M to Advance Doxorubicin-Based Drug into the Clinic
  
• Dutch Ministry Puts Public Vaccine Production Site up for Sale
  
• LGLS Licenses Novavax’ VLP Technology to Develop Flu Vaccines for South Korea and Other Emerging Markets
  
• Kite Pharma Raises $15M in Initial Private Placement to Progress Anticancer Pipeline
  
• Medicago Achieves $3.8M Milestone under DARPA Contract to Build Vaccine Plant
  
• Allergy Therapeutics Firm Anergis Raises $20M in Series A Fundraising
  
• Scientists Find New Mechanism of Glioma Invasion
  
• Biovest and Ordway Research Institute to Evaluate Firm's Technology for Producing Virus-Fighting Products
  
• €1.2M Dutch Credit Will Support Phase I/II Trial of to-BBB’s Brain Cancer Drug
  
• Aduro Licenses Cancer Immunotherapy from BioSante
  
• Oncothyreon Expects to Net $37.4M to Advance Cancer Pipeline
  
• ImmunoCellular Therapeutics to Leverage BioWa’s Antibody Platform
  
• Merck KGaA to Use MDxHealth’s Assay in Second Clinical Glioblastoma Study
  
• Transgene and Vivalis to Evaluate MVA Vaccine Production in EB66 Duck Stem Cell Line
  
• Nabi Stock Plummets as Smoking Cessation Immunotherapy Fails in First Phase III Trial
  
• BioSante Licenses Melanoma Vaccine to Hussman Foundation